Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-18

Study Completion Date

2028-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of Circulating DNA in Blood Samples of Glioma-affected Patients

NCT05964153

Glioma Circulating Tumor Cell

UNKNOWN NA

Biomarkers for Prognosis of Glioblastoma (GBM)

NCT01493219

Glioblastoma

COMPLETED

Image-Guided Stereotactic Biopsy of High Grade Gliomas

NCT00979810

Brain Cancer Glioma

COMPLETED NA

WBSI Guided Personalized Delivery of TTFields

NCT05086497

GBM Glioma Glioblastoma Multiforme Tumor, Brain

RECRUITING NA

Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue

NCT04545177

Glioblastoma

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Glioblastoma Multiforme

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sonobiopsy

* Once enrolled, participants would be prepared for standard of care surgery.
* The sonobiopsy involves the standard procedure for a biopsy, but the biopsy needle is replaced with a customized ultrasound probe, a standard ultrasound contrast agent (microbubbles) is injected intravenously, and the probe is turned on for 3 minutes for the sonobiopsy. Then the planned surgery to remove the tumor will occur.
* An additional brief MRI scan will be obtained using the intraoperative MRI to define imaging changes (if any) that occur as a result of the sonobiopsy procedure. The imaging protocols will include a 3D T2-weighted (T2w) scan, and 3D contrast T1-weighted (T1w) with dynamic contrast enhancement and if time allows T2\* sequence.
* Blood will be collected at several time points.
* A small skin biopsy or another blood draw will be drawn for comparison against the genetic mutations shown in the tumor.
* The blood, tumor, and skin (if applicable) will undergo genetic analysis.

Group Type EXPERIMENTAL

Sonobiopsy

Intervention Type DEVICE

Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy

Research blood

Intervention Type PROCEDURE

No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)

Cancer Personalized Profiling

Intervention Type GENETIC

Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.

Definity®

Intervention Type DEVICE

Being used off-label in this trial

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sonobiopsy

Ultrasound combined with microbubbles to facilitate sampling of biomarkers from brain tumors via blood-based liquid biopsy

Intervention Type DEVICE

Research blood

No more than 10 minutes prior to ultrasound sonication, 10 minutes after ultrasound sonication, 30 minutes after ultrasound sonication (optional at the discretion of the PI), and 60 minutes after ultrasound sonication (optional at the discretion of the PI)

Intervention Type PROCEDURE

Cancer Personalized Profiling

Cancer Personalized Profiling by deep Sequencing will be used to compare the frequency of tumor-specific variants in the blood before and after sonobiopsy.

Intervention Type GENETIC

Definity®

Being used off-label in this trial

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Definity® microbubbles

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be newly diagnosed with a lesion in the brain with imaging characteristics consistent with glioblastoma multiforme. Scan must have occurred no more than 28 days prior to enrollment.
* Lesion must be \> 3 cm in maximal dimension on MRI.
* Lesion must be in the supratentorial space within 5 cm of the cortical surface.
* Lesion must be gadolinium enhancing.
* Low grade tumors and metastatic tumors
* Recurrent brain tumors and/or radiation necrosis
* Must be planning to undergo surgical resection of the tumor.
* Must be at least 18 years old.
* Patients with recurrent GBM who are planning to undergo surgical resection or laser ablation of the recurrent tumor. Recurrence must be confirmed on MRI performed no more than 28 days prior to enrollment.

Exclusion Criteria

* Contraindication to MRI.
* Previous cranial surgery.
* Previous history of cancer and/or cancer treatments.
* Coagulopathy within 14 days of enrollment defined as PT/PTT outside of normal parameters and platelets \< 100,000/mcL.
* Physical skull defect of any kind.
* Ferrous material in the scalp or skull.
* Scalp or skin disease that limits contact with the ultrasound probe.
* Enrolled in another clinical trial where intervention is administered prior to surgery.
* Known hypersensitivity to polyethylene glycol.
* Known unstable cardiopulmonary condition (e.g. acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No